General
Preferred name
SULFISOXAZOLE
Synonyms
sulfafurazole ()
NU-445 ()
Sulfisoxazole127-69-5 ()
SULFISOXAZOLE DIOLAMINE ()
Neazolin ()
NSC-13120 ()
Entusil ()
Sosol ()
Gantrisin ()
Sulfalar ()
Sulfisoxazole component of azo gantrisin ()
NSC-683536 ()
Sulfafurazol ()
Pediazole ()
Soxazole ()
Eryzole ()
Sulphafurazole ()
Sulsoxin ()
Sulfafurazole diethanolamine ()
Sulfisoxazole diethanolamine salt ()
Sulfafurazole diolamine ()
Sulphafurazole diolamine ()
P&D ID
PD001741
CAS
127-69-5
4299-60-9
Tags
available
drug
Approved by
FDA
First approval
1982
1971
Drug indication
Urinary tract infection
osteomyelitis
Drug Status
vet_approved
approved
withdrawn
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Sulfisoxazole (sulfafurazole) is a sulfonamide antibacterial compound .
(GtoPdb)
DESCRIPTION
Sulfisoxazole (Sulfafurazole) is an orally active endothelin receptor antagonist with IC50 values of 0.60 ¦ÌM and 22 ¦ÌM against endothelin receptor A and endothelin receptor B, respectively. Sulfisoxazole is a sulfonamide antibacterial agent with an oxazole substituent. Sulfisoxazole inhibits breast cancer exosome release by targeting endothelin receptor A[1][2].
PRICE
29
DESCRIPTION
Endothelin ETA antagonist
(Tocriscreen Total)
DESCRIPTION
Sulfisoxazole is a sulfonamide antibacterial with an oxazole substituent.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Sulfisoxazole is a sulfonamide antibiotic, it's a short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. It is used for the treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections.
(Enamine Bioactive Compounds)
DESCRIPTION
Sulfisoxazole (Sulfafurazole) is a short-acting sulfonamide antibacterial with activity against a wide range of gram-negative and gram-positive organisms.Sulfisoxazole inhibits breast cancer exosome release by targeting endothelin receptor A.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
29
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocriscreen Total
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
53
Molecular Weight
267.07
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
2
cLogP
1.67
TPSA
98.22
Fraction CSP3
0.18
Chiral centers
0.0
Largest ring
6.0
QED
0.82
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Member status
member
MOA
Endothelin Receptor Antagonists
bacterial antifolate
Indication
urinary tract infections
ATC
J01EB05
S01AB02
Pathway
Autophagy
GPCR/G protein
Microbiology/virology
Anti-infection
Target
antibiotic
Bacterial
Endothelin Receptor
DHPS
Therapeutic Class
Antiinfective Agents
Source data
